A carregar...

PCSK9 inhibitor access barriers—issues and recommendations: Improving the access process for patients, clinicians and payers

The proprotein convertase subtilisin/kexin type 9 inhibitors or monoclonal antibodies likely represent the greatest advance in lipid management in 30 years. In 2015 the US Food and Drug Administration approved both alirocumab and evolocumab for high‐risk patients with familial hypercholesterolemia (...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cardiol
Main Authors: Baum, Seth J., Toth, Peter P., Underberg, James A., Jellinger, Paul, Ross, Joyce, Wilemon, Katherine
Formato: Artigo
Idioma:Inglês
Publicado em: Wiley Periodicals, Inc. 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5412679/
https://ncbi.nlm.nih.gov/pubmed/28328015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.22713
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!